An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer

被引：0

作者：

Spicer, J. ^{[1
]}

Provencio, M. ^{[2
]}

Garrido Lopez, P. ^{[3
]}

Bosch-Barrera, J. ^{[4
]}

de Castro Carpeno, F. J. ^{[5
]}

Felip, E. ^{[6
]}

Trigo, J. ^{[7
]}

Viteri, S. ^{[8
]}

Coart, E. ^{[9
]}

Schmidt, E. ^{[10
]}

Christiansen, A. V. ^{[11
]}

Zocca, M-B. ^{[11
]}

Andersen, M. H. ^{[11
]}

Ehrnrooth, E. ^{[11
]}

Paz-Ares, L. ^{[12
]}

机构：

[1] Kings Coll London, Guys Hosp, London, England

[2] Hosp Puerta del Hierro Majadahonda, Madrid, Spain

[3] Hosp Univ Ramon & Cajal, Madrid, Spain

[4] Hosp Univ Girona Doctor Josep Trueta, Catalan Inst Oncol, Girona, Spain

[5] Hosp Univ HM Sanchinarro, Ctr Integral Oncol Clara Campal, Madrid, Spain

[6] Hosp Univ Vall dHebron, Barcelona, Spain

[7] Hosp Univ Virgen de la Victoria, Inst Invest Biomed Malaga IBIMA, Malaga, Spain

[8] Hosp Univ Quiron Dexeus, Inst Oncol Dr Rosell, Barcelona, Spain

[9] IDDI, Ottignies, Belgium

[10] Merck & Co Inc, Kenilworth, NJ USA

[11] IO Biotech, Copenhagen, Denmark

[12] Hosp Univ 12 Octubre, Madrid, Spain

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

180TiP

引用

页数：2